Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics
smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close […]
Healthy.io Announces Collaboration with Boehringer Ingelheim to Increase Access to Testing for Kidney Disease
Healthy.io, the global leader in transforming the smartphone camera into a medical device, today announced […]
FDA Accepts Supplemental New Drug Application for Jardiance® for Children 10 years and Older with Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for […]
US FDA Accepts Supplemental New Drug Application for Jardiance® for Adults with Chronic Kidney Disease
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) […]
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences today announced they have entered into a strategic collaboration and licensing […]
ArisGlobal Acquires Boehringer Ingelheim’s Signal Analytics Engine, Bringing Enhanced and Unmatched Pharmacovigilance Capabilities to Life Sciences Industry
ArisGlobal, the global market leader in drug safety solutions worldwide, and Boehringer Ingelheim, a leading […]
US FDA Approves Jardiance ® (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction
The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg to […]
Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership
Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more